[Research Report] The High Content Screening market was valued at US$ 1,670.96 million in 2022 to US$ 2,861.56 million by 2031; it is estimated to record a CAGR of 7.2% from 2022 to 2031.

Market Insights and Analyst View:

High-content screening (HCS) is a high-throughput format for cell biology applications that combines quantitative data analysis and automated imaging for large-scale applications, including systems biology and drug discovery. Currently, HCS mostly serves as a fluorescence imaging technique, usually simultaneously measuring a small number of fluorochromes. The drug discovery industry has witnessed a significant surge in the use of HCS due to advancements in automated screening technologies and fluorescence microscopy in recent years. Using an automated fluorescence microscope to image individual cells' subcellular and molecular activities, HCS offers the possibility of quickly screening chemical or siRNA libraries. The most obvious uses of HCS are in primary screenings for possible leads, compounds that can be further refined into therapeutic candidates, or in measures of cellular morphology or other cellular activities that are difficult to measure with a single endpoint, including spatially localized proteins.

Growth Drivers and Challenges:

An increase in research and development activities is driving growth in the market. High-content screening provides biological answers to academic and pharmaceutical questions. Hepatotoxicity, cardiotoxicity, nephrotoxicity, developmental toxicity, genotoxicity, and neurotoxicity are in vitro toxicology applications that employ HCS methodologies. This makes several recently created cellular assay models possible, such as tissues-on-a-chip methods, three-dimensional (3D) cell models, and induced pluripotent stem cells (iPSCs). HCS is also utilized via image data analysis tools, coupling with high-content assays, and genome editing methods (e.g., CRISPR/Cas9).  These methods significantly advance understanding biological processes, creating medications, and simplifying toxicological research.

The HCS market is expanding globally due to research and development in drug discovery. For example, Purdue University, a public land-grant research university, published a report in February 2021 evaluating the impact of IL-27, a heterodimeric cytokine made up of subunits IL-27p28 and EBI3 (Epstein-Barr virus-induced gene 3), on alterations in the gene expression of TC2R prostate adenocarcinoma cells. The TC2R prostate cancer cells' gene expression was altered by RNAi (RNA interference), which was found using high-throughput sequencing (HCS). RNAi targets messenger RNAs that code for those particular proteins.

Despite the enormous processing power, fast connectivity, and reasonably priced data storage that are accessible with modern computers, there are still several important technological challenges that must be made while applying HCS. HCS practitioners frequently discover that third-party analysis software is required to enhance the efficiency of an infrequent test, even though many instruments come with strong, user-friendly image analysis software. In addition, many solutions for data storage, data transfer, and data annotation do not transition well between platforms since there is a lack of standards for image and data formats.

Customize Research To Suit Your Requirement

We can optimize and tailor the analysis and scope which is unmet through our standard offerings. This flexibility will help you gain the exact information needed for your business planning and decision making.

Get 10% FREE CUSTOMIZATION

High Content Screening Market: Strategic Insights

Market Size Value in	US$ 1,670.96 million in 2022
Market Size Value by	US$ 2,861.56 million by 2030
Growth rate	CAGR of 7.2% from 2022 to 2030
Forecast Period	2022-2030
Base Year	2022

Mrinal

Have a question?

Mrinal will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.

 Speak to Analyst

Report Segmentation and Scope:

The high content screening market is segmented into product, application, and end user. By product, the market is segmented into instruments, consumables, software, services, and accessories. By application, the high-content screening market is categorized into primary screening and secondary screening, target identification and validation, toxicity studies, compounds, and others. In terms of end users, the high-content screening market is segmented into pharmaceutical and biotechnology companies, contract research organizations (CROs), and academic and government institutes. The high content screening market, based on geography, is categorized into North America (US, Canada, and Mexico), Europe (France, Germany, Italy, UK, Spain, Benelux, Austria, and Rest of Europe), Asia Pacific (Australia, China, Japan, India, South Korea, Malaysia, Indonesia, and Rest of Asia Pacific), Middle East & Africa (Saudi Arabia, UAE, South Africa, and Rest of Middle East & Africa), and South & Central America (Brazil, Argentina, Rest of South & Central America)

Segmental Analysis:

Based on product, the global high-content screening market is segmented into instruments, consumables, software, services, and accessories. The instruments segment held the largest share of the market in 2022. Since high-content screening technologies are used to visualize and interpret cellular images, they are essential for toxicology, drug development, and basic cell biology research. These state-of-the-art devices have many features, such as high throughput capability, automated imaging and analysis, and the ability to do difficult experiments.

High-content screening software is used in picture analysis, data management, and assay design. The time and cost of manual analysis can be reduced using sophisticated software that can automate certain high-content screening processes, thanks to artificial intelligence and machine learning breakthroughs. A further factor contributing to the expected strong demand for high-content screening software is the growing interest in precision and personalized medicine, which can assist in creating medicines specifically tailored to individual patients' needs.

By application, the high-content screening market is segmented into target identification and validation, primary screening and secondary screening, toxicity studies, compounds, and others. 2022 the toxicity studies segment is estimated to grow at the highest CAGR. Because high-content screening can identify compounds that damage cells, it is essential for toxicity investigations. A range of tests can be performed to assess a substance's effects on cell viability, proliferation, and apoptosis. Software and technologies for high-content screening can be used for these assays. Furthermore, high-content screening helps researchers identify any safety concerns early in the drug development process by examining the toxicity processes of chemicals.

By end user, the high content screening market is categorized into academic and government institutes, pharmaceuticals and biotechnology companies, and contract research organizations (CROs). The pharmaceuticals and biotechnology companies segment held the largest share of the market in 2022. High-content screening dominates this market because the biotechnology and pharmaceutical industries utilize it extensively in preclinical and clinical investigations. Its use in academia and the pharmaceutical industry has grown to the point where it is now a vital tool for drug research and discovery. High-content assays have a greater potential to aid in drug development now that cellular assay technologies have advanced to the point where three-dimensional (3D) cultures, genome editing tools (e.g., CRISPR/Cas9), and induced pluripotent stem cells (iPSCs).

Regional Analysis: 

Based on geography, the high content screening market is categorized into five key regions—North America, Europe, Asia Pacific, South & Central America, and the Middle East & Africa. Asia Pacific is anticipated to register the highest CAGR during the forecast period. As a result of the growing need for drug research and development in emerging countries such as China and India, the high-content screening products market in the Asia Pacific is expected to grow quickly.

High Content Screening Market Trend: 

Automated Microscope Based High Content Screening

Automated microscope-based high-content screening has gained substantial momentum recently due to its capability to study many features simultaneously in complicated biology systems. HCS is used all along the preclinical drug discovery pipeline. It can identify and validate new drug targets or lead compounds, predict in vivo toxicity, and suggest pathways or molecular targets of compounds. HCS also used to support clinical trials, such as companion diagnostics. Consequent High-Content Screening (HCS) solutions for testing the possible toxicity of chemicals and complicated substances are being implemented by pharmaceutical companies to improve in-vitro toxicity testing by reducing the cost and time. The increasing number of CROs providing HCS outsourcing services and applying HCS in personalized medicine presents a significant trend in the market. High-content screening microscopy is a rapidly evolving technology that can be applied to extract rich quantitative information about cell form and function.

Competitive Landscape and Key Companies:

A few of the prominent players operating in the global high content screening market are GE Healthcare, Danaher Corporation, Thermo Fisher Scientific Inc., PerkinElmer, Tecan Group, Bio Tek Instruments Inc., Becton, Dickinson, Bio-Rad Laboratories, Yokogawa Electric Corporation, and Merk Millipore. These companies focus on developing new technologies, advancing existing products, expanding their geographic footprint to meet the growing consumer demand worldwide, and expanding their product range in specialty portfolios. Companies operating in the global high-content screening market implement various inorganic and organic strategies. A few of them are mentioned below:

• In September 2022, BD (Becton, Dickinson, and Company) launched BD Research Cloud, a cloud-based software solution intended to streamline the flow cytometry workflow to empower higher-quality experiments with faster time to insight for scientists working across a range of disciplines, including virology, immunology, oncology, and infectious disease monitoring.
• In March 2022, Beckman Coulter Life Sciences introduced a powerful solution to manual sample preparation and data management bottlenecks in clinical flow cytometry: the CellMek SPS. This fully automated sample preparation system (SPS) offers on-demand processing for many sample types to help laboratories expand their capabilities.